<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B"
alink="#FF0000">
<h4>
<font face="Times New Roman,Times">Company Information</font></h4>
<p><br><font face="Times New Roman,Times">AngioGenetics Sweden AB is a
Gothenburg-based biotech company focusing on drug discovery in the
therapeutic
area of angiogenesis, new blood vessel formation. AngioGenetics has
exceptionally
strong research in this area, based on a world leading research
tradition.</font>
<p><font face="Times New Roman,Times">Regulating angiogenesis in the
human
tissue could revolutionize the treatment of cancer, coronary heart
disease,
and complications from diabetes, jointly the cause of death for the
vast
majority of the population of the western world.</font>
<p><font face="Times New Roman,Times">AngioGenetics focuses on the
early
stages of drug discovery and will license its patented research
findings/products
to pharmaceutical companies for further development. AngioGenetics
identifies
and validates drug targets mainly through in-house research and aims to
identify, optimize, and evaluate leads for these targets through
contract
research and alliances. Lead series and candidate drugs will be
licensed
out to pharmaceutical companies, who will perform clinical trials and
bring
the developed drug to market.</font>
<p><font face="Times New Roman,Times">For more information please
contact:</font>
<p><font face="Times New Roman,Times">Mattias Kalén, CEO</font>
<p><font face="Times New Roman,Times">AngioGenetics AB</font>
<br><font face="Times New Roman,Times">Medicinaregatan 7B</font>
<br><font face="Times New Roman,Times">P.O. Box 440</font>
<br><font face="Times New Roman,Times">SE-405 30, Gothenburg,
Sweden</font>
<p><font face="Times New Roman,Times">Tel: +46 31 773 3553</font>
<br><font face="Times New Roman,Times">Fax: +46 31 773 3969</font>
<br><font face="Times New Roman,Times">Cell: +46 70 871 7000</font>
<br> <font face="Times New Roman,Times">Mail: <a
href="mailto:information"at"angiogenetics.se">information@angiogenetics.se</a></font>
<br>
</body>